Cloud PRwire

Atossa Therapeutics announces further patent protection for Endoxifen

–News Direct–

Atossa Therapeutics CEO Dr Steven Quay joined Steve Darling from Proactive to share news the company has been granted a new patent directed to enterically encapsulated endoxifen compositions formulated as a suspension by the United States Patent and Trademark Office. These will include all liquid suspension formulations suitable for oral administration and dispersible tablets, powders, granules, pellets, or sprinkles for reconstitution.

Endoxifen is now protected by three issued US patents and numerous pending patents. Dr Quay emphasized the importance of intellectual property and ongoing patent activities to protect the company's innovations and facilitate potential partnerships with larger pharmaceutical companies.

He told Proactive this is an important patent as the company learns more about the potential therapeutic role of endoxifen beyond breast cancer and mammographic breast density. The company also shares more details about suspension formulation and when and how it can be used.

Contact Details

Proactive Investors

+1 604-688-8158

View source version on

Atossa Therapeutics Inc

comtex tracking